Agenda

  • 15:00
    Keynote: The Janssen Oncology Innovation Landscape
  • 15:30
    Panel: Next Wave in Immune Engagers – Harnessing Early Innovation
  • 16:30
    Break
  • 16:40
    Partnering with Johnson & Johnson Innovation
  • 17:10
    Interactive Science Sessions (breakout virtual rooms)
  • 18:00
    Event close

    Webinar: Next Wave of Immune Engagers in Hematological Malignancies

    starts:07/09/2021 ends:07/09/2021 from:15:00 to:18:00 organizer: address:Virtual mobile:+31(0)6-15 429 544 email: nwheele3@its.jnj.com www: Link >> Import to calendar

    Venue: Virtual

    Date: 07/09/2021

    Time: 15:00 - 18:00

    Johnson & Johnson Innovation virtual event
    Next Wave of Immune Engagers in Hematological Malignancies
    7 September 2021, 15:00 – 18:00 hours CEST

    The discovery and development of T-cell redirecting modalities, such as bispecific antibodies and CAR-Ts, holds great promise for patients with multiple myeloma and other hematological malignancies, such as lymphoma and acute myeloid leukemia.

    Johnson & Johnson Innovation, in collaboration with Janssen Research & Development, LLC’s Oncology Therapeutic Area, will host a virtual scientific and strategic partnering event on state-of-the-art developments in immune cell engagers in hematological malignancies, bringing together entrepreneurs, start-ups, researchers, and scientists from across Europe and beyond. They also want to explore how Johnson & Johnson Innovation could collaborate with the aim to support opportunities and enable innovators and their innovations to reach full therapeutic potential for patients.

    DANSK BIOTEK members are most welcome to join on September 7. Registration and information on speakers can be found here.

    If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

    Copyright 2021 Danskbiotek. All rights reserved.